Alector, Inc. (NasdaqGS: ALEC)
Health Care · Biotechnology · US
$2.35
+1.96% today · -1.7% 1Y
Alector, Inc. (NasdaqGS: ALEC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $256.81M and employs 103 people.
Over the last twelve months the share price has lost 1.7%, trading between 1.09 and 3.40.
Tweenvest scores Alector, Inc. across four factors: quality 22/100, value 44/100, growth 0/100. Its strongest factor is value.
ALEC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $256.81M
- Revenue (TTM)
- $13.86M
- P/E
- —
- EPS
- -1.09
- Dividend yield
- —
- Beta (5Y)
- 0.58
- 52-week high
- $3.40
- 52-week low
- $1.09
- Avg volume (3M)
- —
- Shares outstanding
- 111.66M
- Employees
- 103
- Next earnings
- —
About Alector, Inc.
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
- ISIN
- US0144421072
- Founded
- 2013
- Listed since
- Feb 7, 2019
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $266.26 | +0.66% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $444.18 | +0.08% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.42 | +1.14% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $553.77 | +1.13% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $834.60 | +0.74% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $156.25 | +12.50% |
Figures last refreshed Aug 18, 2026.